MGMT Status as a Clinical Biomarker in Glioblastoma

甲基化 替莫唑胺 胶质母细胞瘤 甲基转移酶 DNA甲基化 生物标志物 肿瘤科 医学 内科学 生物信息学 生物 癌症研究 基因表达 基因 遗传学
作者
Madison Butler,Lőrinc Sándor Pongor,Yuting Su,Liqiang Xi,Mark Raffeld,Martha Quezado,Jane B. Trepel,Kenneth Aldape,Yves Pommier,Jing Wu
出处
期刊:Trends in cancer [Elsevier BV]
卷期号:6 (5): 380-391 被引量:322
标识
DOI:10.1016/j.trecan.2020.02.010
摘要

MGMT promoter methylation status is a widely accepted biomarker in glioblastoma. Inconsistencies between MGMT promoter methylation status and expression level have raised the question of the value of promoter methylation status in predicting patient response to temozolomide treatment in glioblastoma. Combined evaluation of MGMT methylation and expression and/or mismatch repair proficiency may provide better insight into a personalized treatment approach. Understanding the molecular and genetic mechanisms regulating MGMT expression beyond promoter methylation is essential to enhance the utility of MGMT status as a biomarker in treatment decision-making for glioblastoma patients. Glioblastoma is the most common primary malignant brain tumor. Although current standard therapy extends median survival to ~15 months, most patients do not have a sustained response to treatment. While O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) promoter methylation status is accepted as a prognostic and promising predictive biomarker in glioblastoma, its value in informing treatment decisions for glioblastoma patients remains debatable. Discrepancies between MGMT promoter methylation status and treatment response in some patients may stem from inconsistencies between MGMT methylation and expression levels in glioblastoma. Here, we discuss MGMT as a biomarker and elucidate the discordance between MGMT methylation, expression, and patient outcome, which currently challenges the implementation of this biomarker in clinical practice. Glioblastoma is the most common primary malignant brain tumor. Although current standard therapy extends median survival to ~15 months, most patients do not have a sustained response to treatment. While O6-methylguanine (O6-MeG)-DNA methyltransferase (MGMT) promoter methylation status is accepted as a prognostic and promising predictive biomarker in glioblastoma, its value in informing treatment decisions for glioblastoma patients remains debatable. Discrepancies between MGMT promoter methylation status and treatment response in some patients may stem from inconsistencies between MGMT methylation and expression levels in glioblastoma. Here, we discuss MGMT as a biomarker and elucidate the discordance between MGMT methylation, expression, and patient outcome, which currently challenges the implementation of this biomarker in clinical practice. additional cancer treatment given after the primary treatment to decrease the risk of cancer recurrence. a class of anticancer drugs that interfere with cell DNA to kill tumor cells. a type of tumor originating from brain or spinal cord cells called astrocytes. a class of brain tumors that arise from cells called glia that surround and support nerve cells. an epigenetic mechanism where methyl groups are added to DNA molecules (in the context of DNA methylation), often modifying gene expression and function; promoter methylation refers to the addition of methyl groups to DNA sequences in the promoter region of a gene. a specialty that involves the management and study of central nervous system cancers, including tumors of the brain and spinal cord. (The Cancer Genome Atlas - Glioblastoma Multiforme) a dataset of glioblastoma as part of The Cancer Genome Atlas program that is built for cancer research. the transplantation of tissue or cells to an individual of another species. In this opinion article, it refers to a model of human tumor grown in immunodeficient mice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
狂野灵波完成签到,获得积分10
刚刚
智慧钦关注了科研通微信公众号
1秒前
王晨发布了新的文献求助10
1秒前
小二郎的应助被leo采纳,获得10
1秒前
1秒前
1秒前
深情安青的应助被SLL采纳,获得10
2秒前
st5114完成签到,获得积分20
3秒前
二二春发布了新的文献求助10
3秒前
3秒前
Akim的应助被王亚奇采纳,获得10
3秒前
宋清华发布了新的文献求助10
3秒前
3秒前
锂离子发布了新的文献求助10
3秒前
Outlier发布了新的文献求助30
4秒前
4秒前
没礼貌的小气鬼完成签到,获得积分10
4秒前
不吃香菜完成签到,获得积分10
5秒前
安安公主发布了新的文献求助10
5秒前
玖可柒发布了新的文献求助10
5秒前
6秒前
顾村完成签到,获得积分20
6秒前
6秒前
Nole的应助被never采纳,获得10
6秒前
7秒前
SHRA1811完成签到 ,获得积分10
7秒前
8秒前
李麟发布了新的文献求助10
8秒前
学术混子发布了新的文献求助10
9秒前
Tuuuuu的应助被小卢采纳,获得10
10秒前
10秒前
一一发布了新的文献求助10
11秒前
11秒前
wofos完成签到,获得积分10
11秒前
机智笑南完成签到,获得积分10
11秒前
星辰大海的应助被宋清华采纳,获得30
11秒前
wenjiang发布了新的文献求助10
12秒前
12秒前
脑洞疼的应助被这次会赢吗采纳,获得10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188013
求助须知:如何正确求助?哪些是违规求助? 9575913
关于积分的说明 21844012
捐赠科研通 7785789
什么是DOI,文献DOI怎么找? 3435148
关于科研通互助平台的介绍 2559521
邀请新用户注册赠送积分活动 2482051